|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
CA1310924C
(en)
|
1986-04-24 |
1992-12-01 |
Francis P. Mccormick |
Infective drug delivery system
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
US5011912A
(en)
|
1986-12-19 |
1991-04-30 |
Immunex Corporation |
Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
|
|
US4970154A
(en)
|
1987-10-09 |
1990-11-13 |
Baylor College Of Medicine |
Method for inserting foreign genes into cells using pulsed radiofrequency
|
|
US4965195A
(en)
|
1987-10-26 |
1990-10-23 |
Immunex Corp. |
Interleukin-7
|
|
EP0315456B1
(en)
|
1987-11-05 |
1994-06-01 |
Hybritech Incorporated |
Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
|
|
US4892538A
(en)
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
|
US5106627A
(en)
|
1987-11-17 |
1992-04-21 |
Brown University Research Foundation |
Neurological therapy devices
|
|
US5158881A
(en)
|
1987-11-17 |
1992-10-27 |
Brown University Research Foundation |
Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
|
|
US4968607A
(en)
|
1987-11-25 |
1990-11-06 |
Immunex Corporation |
Interleukin-1 receptors
|
|
US5011472A
(en)
|
1988-09-06 |
1991-04-30 |
Brown University Research Foundation |
Implantable delivery system for biological factors
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5288855A
(en)
|
1989-01-23 |
1994-02-22 |
Farmitalia Carlo Erba |
Extracellular form of the human fibroblast growth factor receptor
|
|
JP3039802B2
(ja)
|
1989-07-06 |
2000-05-08 |
ザ リージェンツ オブザ ユニバーシティ オブ カリフォルニア |
繊維芽細胞成長因子のための受容体
|
|
US5683888A
(en)
|
1989-07-22 |
1997-11-04 |
University Of Wales College Of Medicine |
Modified bioluminescent proteins and their use
|
|
US5676954A
(en)
|
1989-11-03 |
1997-10-14 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
|
ATE156189T1
(de)
|
1989-12-22 |
1997-08-15 |
Applied Research Systems |
Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination
|
|
US5292658A
(en)
|
1989-12-29 |
1994-03-08 |
University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center |
Cloning and expressions of Renilla luciferase
|
|
WO1991010470A1
(en)
|
1990-01-08 |
1991-07-25 |
Brown University Research Foundation |
Devices and methods for enhanced delivery of active factors
|
|
ATE139258T1
(de)
|
1990-01-12 |
1996-06-15 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US5672510A
(en)
|
1990-01-19 |
1997-09-30 |
Genetic Therapy, Inc. |
Retroviral vectors
|
|
WO1991018982A1
(en)
|
1990-06-05 |
1991-12-12 |
Immunex Corporation |
Type ii interleukin-1 receptors
|
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5217889A
(en)
|
1990-10-19 |
1993-06-08 |
Roninson Igor B |
Methods and applications for efficient genetic suppressor elements
|
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
|
US5229501A
(en)
|
1991-01-11 |
1993-07-20 |
Chiron Corporation |
Expression and use of human fibroblast growth factor receptor
|
|
ES2142801T3
(es)
|
1991-03-11 |
2000-05-01 |
Univ Georgia Res Found |
Clonacion y expresion de luciferasa de renilla.
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
CA2111348A1
(en)
|
1991-06-14 |
1992-12-23 |
John S. Logan |
Production of human hemoglobin in transgenic pigs
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP0593592B1
(en)
|
1991-07-08 |
1998-03-25 |
The University Of Massachusetts At Amherst |
Thermotropic liquid crystal segmented block copolymer
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
IL100219A0
(en)
|
1991-12-02 |
1992-09-06 |
Yeda Res & Dev |
Variable region within fibroblast growth factor receptors that confers ligand specificity
|
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
|
US5234784A
(en)
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
|
US5364791A
(en)
|
1992-05-14 |
1994-11-15 |
Elisabetta Vegeto |
Progesterone receptor having C. terminal hormone binding domain truncations
|
|
WO1994000599A2
(en)
|
1992-06-18 |
1994-01-06 |
Whittier Institute For Diabetes And Endocrinology |
Process for detection of neoplastic disease
|
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
|
JP3589665B2
(ja)
|
1992-10-23 |
2004-11-17 |
イミュネックス・コーポレーション |
可溶性オリゴマー蛋白質の調製法
|
|
US5489743A
(en)
|
1993-01-19 |
1996-02-06 |
Amgen Inc. |
Transgenic animal models for thrombocytopenia
|
|
US5581476A
(en)
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
|
US6664107B1
(en)
|
1993-05-26 |
2003-12-16 |
Ontario Cancer Institute, University Health Network |
CD45 disrupted nucleic acid
|
|
CA2161015A1
(en)
|
1993-05-26 |
1994-12-08 |
Tak Wah Mak |
Transgenic mammals lacking expression of particular cd45 isoforms
|
|
US5589362A
(en)
|
1993-06-14 |
1996-12-31 |
Basf Aktiengesellschaft |
Tetracycline regulated transcriptional modulators with altered DNA binding specificities
|
|
US5654168A
(en)
|
1994-07-01 |
1997-08-05 |
Basf Aktiengesellschaft |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
|
|
WO1994029442A2
(en)
|
1993-06-14 |
1994-12-22 |
Basf Aktiengesellschaft |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
AU7568094A
(en)
|
1993-08-12 |
1995-03-14 |
Cytotherapeutics, Inc. |
Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
|
|
DE69435112D1
(de)
|
1993-09-10 |
2008-08-21 |
Univ Columbia |
Verwendung von grünem fluoreszenzprotein
|
|
WO1995021191A1
(en)
|
1994-02-04 |
1995-08-10 |
William Ward |
Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US5777079A
(en)
|
1994-11-10 |
1998-07-07 |
The Regents Of The University Of California |
Modified green fluorescent proteins
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
CZ372297A3
(cs)
|
1995-05-26 |
1998-03-18 |
Zeneca Limited |
Přepínání genové exprese využívající receptoru pro ekdyson
|
|
WO1996040958A1
(en)
|
1995-06-07 |
1996-12-19 |
Baylor College Of Medicine |
Nucleic acid transporters for delivery of nucleic acids into a cell
|
|
WO1996041865A1
(en)
|
1995-06-07 |
1996-12-27 |
Ariad Gene Therapeutics, Inc. |
Rapamcycin-based regulation of biological events
|
|
US5874304A
(en)
|
1996-01-18 |
1999-02-23 |
University Of Florida Research Foundation, Inc. |
Humanized green fluorescent protein genes and methods
|
|
US5804387A
(en)
|
1996-02-01 |
1998-09-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
FACS-optimized mutants of the green fluorescent protein (GFP)
|
|
US5876995A
(en)
|
1996-02-06 |
1999-03-02 |
Bryan; Bruce |
Bioluminescent novelty items
|
|
ATE465149T1
(de)
|
1996-02-28 |
2010-05-15 |
Ariad Pharma Inc |
Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US5679559A
(en)
|
1996-07-03 |
1997-10-21 |
University Of Utah Research Foundation |
Cationic polymer and lipoprotein-containing system for gene delivery
|
|
US5925558A
(en)
|
1996-07-16 |
1999-07-20 |
The Regents Of The University Of California |
Assays for protein kinases using fluorescent protein substrates
|
|
US5976796A
(en)
|
1996-10-04 |
1999-11-02 |
Loma Linda University |
Construction and expression of renilla luciferase and green fluorescent protein fusion genes
|
|
US6214795B1
(en)
|
1996-11-12 |
2001-04-10 |
Praecis Pharmaceuticals, Inc. |
Peptide compounds useful for modulating FGF receptor activity
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
JP3795533B2
(ja)
|
1996-12-12 |
2006-07-12 |
プロルーム・リミテツド |
感染性物質を検出及び同定するための方法及び装置
|
|
KR20000062345A
(ko)
|
1996-12-26 |
2000-10-25 |
히라타 다다시 |
신규 폴리펩타이드, 신규 ｄｎａ 및 신규 항체
|
|
CA2196496A1
(en)
|
1997-01-31 |
1998-07-31 |
Stephen William Watson Michnick |
Protein fragment complementation assay for the detection of protein-protein interactions
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
US6150098A
(en)
|
1998-02-20 |
2000-11-21 |
Amgen Inc. |
Methods for identifying novel secreted mammalian polypeptides
|
|
WO1999049019A2
(en)
|
1998-03-27 |
1999-09-30 |
Prolume, Ltd. |
Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
|
|
US20020142374A1
(en)
|
1998-08-17 |
2002-10-03 |
Michael Gallo |
Generation of modified molecules with increased serum half-lives
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
WO2000054813A2
(en)
|
1999-03-15 |
2000-09-21 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
CA2311201A1
(en)
|
1999-08-05 |
2001-02-05 |
Genset S.A. |
Ests and encoded human proteins
|
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
AU7368100A
(en)
|
1999-09-10 |
2001-04-10 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
|
WO2001032678A1
(en)
|
1999-11-05 |
2001-05-10 |
Smithkline Beecham Corporation |
sbgFGF-19a
|
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
|
ES2335386T3
(es)
|
1999-11-18 |
2010-03-26 |
Novartis Vaccines And Diagnostics, Inc. |
Gen fgf-21 humano y productos de expresion genica.
|
|
AU1628101A
(en)
|
1999-11-22 |
2001-06-04 |
Millennium Pharmaceuticals, Inc. |
Jaffa, a novel fibroblast growth factor family member and uses therefor
|
|
GB9928787D0
(en)
|
1999-12-03 |
2000-02-02 |
Medical Res Council |
Direct screening method
|
|
US7108984B2
(en)
|
2000-01-12 |
2006-09-19 |
Mount Sinai School Of Medicine |
Methods of identifying modulators of the FGF receptor
|
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
|
WO2001049849A1
(en)
|
2000-01-05 |
2001-07-12 |
Zymogenetics, Inc. |
Novel fgf homolog zfgf11
|
|
AU5056501A
(en)
|
2000-03-31 |
2001-10-08 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
|
GB0025144D0
(en)
|
2000-10-13 |
2000-11-29 |
Medical Res Council |
Concatenated nucleic acid sequences
|
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
|
US20060223114A1
(en)
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
US20040018499A1
(en)
|
2001-06-06 |
2004-01-29 |
Lal Preeti G |
Extracellular messengers
|
|
JP4444652B2
(ja)
|
2001-07-11 |
2010-03-31 |
マキシゲン・ホールディングズ・リミテッド |
Ｇ−ｃｓｆ結合体
|
|
AU2002322394A1
(en)
|
2001-07-30 |
2003-02-17 |
Eli Lilly And Company |
Method for treating diabetes and obesity
|
|
WO2003038054A2
(en)
|
2001-10-31 |
2003-05-08 |
New York University |
Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
|
|
JP2005519891A
(ja)
|
2002-01-15 |
2005-07-07 |
イーライ・リリー・アンド・カンパニー |
危篤状態の患者における罹病率および死亡率を低下させる方法
|
|
DE60336452D1
(de)
|
2002-01-31 |
2011-05-05 |
Max Planck Gesellschaft |
Fgfr agoniste
|
|
EP1332761A1
(en)
|
2002-01-31 |
2003-08-06 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonists of fibroblast growth factor receptors (FGFR)
|
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
|
US20040202995A1
(en)
|
2003-04-09 |
2004-10-14 |
Domantis |
Nucleic acids, proteins, and screening methods
|
|
NZ543292A
(en)
|
2003-06-12 |
2008-04-30 |
Lilly Co Eli |
GLP-1 analog fusion proteins
|
|
US20070253966A1
(en)
|
2003-06-12 |
2007-11-01 |
Eli Lilly And Company |
Fusion Proteins
|
|
PL1680140T3
(pl)
|
2003-10-16 |
2011-11-30 |
Imclone Llc |
Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
|
|
WO2005061712A1
(en)
|
2003-12-10 |
2005-07-07 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
WO2005072769A1
(en)
|
2004-01-26 |
2005-08-11 |
Eli Lilly And Company |
Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
|
|
CA2557782A1
(en)
|
2004-03-17 |
2005-10-06 |
Eli Lilly And Company |
Glycol linked fgf-21 compounds
|
|
JP4505631B2
(ja)
|
2004-03-31 |
2010-07-21 |
独立行政法人産業技術総合研究所 |
ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
|
|
PT1751184E
(pt)
|
2004-05-13 |
2009-11-10 |
Lilly Co Eli |
Proteínas de fusão de fgf-21
|
|
WO2006028714A1
(en)
|
2004-09-02 |
2006-03-16 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
SI1789442T1
(sl)
|
2004-09-02 |
2010-01-29 |
Lilly Co Eli |
Proteinske mutante fibroblastnega rastnega faktorja 21
|
|
EP3061461A1
(en)
|
2004-10-29 |
2016-08-31 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
EP1831371A2
(en)
|
2004-12-14 |
2007-09-12 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
EP1846019A2
(en)
|
2005-01-21 |
2007-10-24 |
Eli Lilly And Company |
Method for treating cardiovascular disease
|
|
JP2006246823A
(ja)
|
2005-03-11 |
2006-09-21 |
Kyoto Univ |
造血因子としてのＦｇｆ２１の使用
|
|
WO2006130527A2
(en)
|
2005-05-31 |
2006-12-07 |
Novartis Ag |
Mutations and polymorphisms of fibroblast growth factor receptor 1
|
|
EP1910542B1
(en)
|
2005-07-22 |
2009-12-02 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with fgfr fusion proteins
|
|
US8043833B2
(en)
|
2005-10-31 |
2011-10-25 |
Novo Nordisk A/S |
Expression of soluble therapeutic proteins
|
|
CA2644046A1
(en)
|
2006-02-28 |
2007-09-07 |
Trustees Of Boston University |
Metabolic regulators and uses thereof
|
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
WO2008066498A1
(en)
|
2006-12-01 |
2008-06-05 |
Agency For Science, Technology And Research |
Cancer-related protein kinases
|
|
ES2385114T3
(es)
|
2007-03-30 |
2012-07-18 |
Ambrx, Inc. |
Polipéptidos de FGF-21 modificados y sus usos
|
|
ES2665996T3
(es)
|
2007-04-02 |
2018-04-30 |
Genentech, Inc. |
Anticuerpo agonista de klotho-beta para utilizar en el tratamiento de diabetes mellitus o resistencia a la insulina
|
|
JP5187837B2
(ja)
|
2007-04-06 |
2013-04-24 |
独立行政法人産業技術総合研究所 |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
|
US7537903B2
(en)
*
|
2007-04-23 |
2009-05-26 |
Board Of Regents, The University Of Texas System |
FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
|
|
KR20100017169A
(ko)
|
2007-05-22 |
2010-02-16 |
노파르티스 아게 |
Ｆｇｆ２１-관련 장애의 치료, 진단 및 검출 방법
|
|
WO2008151258A2
(en)
|
2007-06-04 |
2008-12-11 |
Neose Technologies, Inc. |
O-linked glycosylation using n-acetylglucosaminyl transferases
|
|
JP2010535781A
(ja)
|
2007-08-03 |
2010-11-25 |
イーライ リリー アンド カンパニー |
肥満に対する処置
|
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
SG10201402038WA
(en)
|
2009-05-05 |
2014-07-30 |
Amgen Inc |
FGF21 Mutants And Uses Thereof
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|